NLM Digital Collections

Search

Search Constraints

Start Over You searched for: Formats Text Remove constraint Formats: Text Languages English Remove constraint Languages: English Recently Added Within 6 Months Remove constraint Recently Added: Within 6 Months
Number of results to display per page

Search Results

2. 30-Day notices, 135-day premarket approval (PMA) supplements and 75-day humanitarian device exemption (HDE) supplements for manufacturing method or process changes: guidance for industry and Food and Drug Administration staff

nlm:nlmuid-101760040-pdf

7. Access to health insurance

nlm:nlmuid-101762170-pdf

10. Adaptive designs for clinical trials of drugs and biologics

nlm:nlmuid-101760568-pdf

16. Administrative rulemaking

nlm:nlmuid-101762303-pdf

17. Adolescent and young adult substance use: federal grants for prevention, treatment, and recovery services and for research : report to Congressional committees

nlm:nlmuid-101766079-pdf

21. Amyotrophic lateral sclerosis: developing drugs for treatment

nlm:nlmuid-101760442-pdf

24. Anatomy, descriptive and surgical

nlm:nlmuid-101532317-bk

28. Artificial opening of pulmonary cavities, insertion of rubber tube and injection of chlorine gas: read before the Section of Surgery and Anatomy at the Forty-fourth Annual Meeting of the American Medical Association

nlm:nlmuid-101752060-bk

29. As it grows, Medicare Advantage is enrolling more low-income and medically complex beneficiaries: recent trends in beneficiary clinical characteristics, health care utilization, and spending

nlm:nlmuid-101769562-pdf

30. As there has been published by the American Antivivisection Society a pamphlet "Facts in regard to the failure of the bills presented to the legislature for the restriction of vivisection"

nlm:nlmuid-101661206-bk

36. Bacterial risk control strategies for blood collection establishments and transfusion services to enhance the safety and availability of platelets for transfusion

nlm:nlmuid-101760477-pdf

39. Bending the obesity cost curve: reducing obesity rates by five percent could lead to more than $29 billion in health care savings in five years

nlm:nlmuid-101587049-pdf

40. Benefits and services

nlm:nlmuid-101762397-pdf

48. Bundled-payment models around the world: how they work and what their impact has been

nlm:nlmuid-101769557-pdf

49. Business of health insurance

nlm:nlmuid-101762179-pdf

51. Business practices

nlm:nlmuid-101762433-pdf

57. Canary in a coal mine?: a look at initial data on COVID-19's impact on U.S. hospitals

nlm:nlmuid-101769564-pdf

70. Changes to existing medical software policies resulting from section 3060 of the 21st Century Cures Act: guidance for industry and Food and Drug Administration staff

nlm:nlmuid-101760473-pdf

74. Chemistry, manufacturing, and control (CMC) information for human gene therapy investigational new drug applications (INDs)

nlm:nlmuid-101767656-pdf

76. Citizen petitions and petitions for stay of action subject to section 505(q) of the Federal Food, Drug, and Cosmetic Act

nlm:nlmuid-101760431-pdf

77. Class II special controls guideline: in vitro diagnostic devices for Bacillus spp. detection : guideline for industry and Food and Drug Administration staff

nlm:nlmuid-101760039-pdf

78. Classification and requirements for laser illuminated projectors (LIPs): (Laser Notice No. 57) : guidance for industry and Food and Drug Administration staff

nlm:nlmuid-101760067-pdf

80. Clinical drug interaction studies: cytochrome P450 enzyme- and transporter-mediated drug interactions

nlm:nlmuid-101767654-pdf

86. Coast Guard health records: timely acquisition of new system is critical to overcoming challenges with paper process : testimony before the Subcommittee on Coast Guard and Maritime Transportation, Committee on Transportation and Infrastructure, House of Representatives

nlm:nlmuid-101765784-pdf

89. Compliance policy for certain compounding of oral oxitriptan (5-HTP) drug products for patients with tetrahydrobiopterin (BH4) deficiency: immediately in effect guidance for industry

nlm:nlmuid-101760257-pdf

90. Compliance policy for limited modifications to certain marketed tobacco products

nlm:nlmuid-101760563-pdf

93. Consideration of uncertainty in making benefit-risk determinations in medical device premarket approvals, de novo classifications, and humanitarian device exemptions: guidance for industry and Food and Drug Administration staff

nlm:nlmuid-101760383-pdf

94. Considerations for the development of dried plasma products intended for transfusion

nlm:nlmuid-101760572-pdf

95. Considerations for the inclusion of adolescent patients in adult oncology clinical trials

nlm:nlmuid-101760009-pdf

96. Considerations in demonstrating interchangeability with a reference product

nlm:nlmuid-101760108-pdf

98. Contraceptive access, choice, and utilization: a survey of Mississippi women

nlm:nlmuid-101760649-pdf

100. Coordinated development of antimicrobial drugs and antimicrobial susceptibility test devices: guidance for industry and Food and Drug Administration staff

nlm:nlmuid-101759953-pdf